Literature DB >> 8635069

The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly.

M H Werner1, S Phuphanich, G H Lyman.   

Abstract

BACKGROUND: Studies indicate that the incidence of primary malignant brain tumors in the elderly is increasing, but this may reflect increased case ascertainment due to the introduction of computed tomography (CT) scanning. In addition, tumor histology was not available in these studies. This study was conducted to determine whether the incidence of primary malignant brain tumors in the elderly in Florida is increasing and to verify the histology of these increases.
METHODS: Using the number of primary malignant brain tumors reported to the Florida Cancer Data System (FCDS) when CT scanning was available, incidence rates per 100,000 people were calculated. Incidence density ratios (IDRs) were calculated for 1986-1989 relative to 1981-1984.
RESULTS: Tumor incidence at ages 20-64 years increased from 5.7 in 1981-1984 to 5.9 in 1986-1989, with an IDR of 1.05 (not significant). The incidence in those aged 65 years or older rose from 14.8 to 18.3, with an IDR of 1.23 (P < 0.001). The increase was 15% in those aged 65-69, 16% in those 70-74 years, 30% in those 75-79 years, 36% in those 80-84 years, and 254% in those 85 years or older. Indicence density ratios in those aged 65 years or older were 0.92 (not significant) for astrocytoma, 2.7 (p < 0.001) for anaplastic astrocytoma, 1.32 (p < 0.001) for glioblastoma and 3.56 (p < 0.001) for lymphoma. In those aged 65+ the incidence of all cancers rose 7.6% (not significant), and the incidence of pancreatic cancer (another neoplasm that requires CT scanning for diagnosis) rose 0.34% (not significant).
CONCLUSIONS: The incidence of primary brain tumors in elderly Floridians has increased. This increase is independent of increased case ascertainment associated with the introduction of CT scanning and independent of a general increase of all cancers. The rise in brain tumor incidence is observed in anaplastic astrocytoma, glioblastoma, and lymphoma but not astrocytoma. This study confirms the increase is histologically specific and not due to increased case ascertainment. Further investigation into the etiology of this increase is warranted.

Entities:  

Mesh:

Year:  1995        PMID: 8635069     DOI: 10.1002/1097-0142(19951101)76:9<1634::aid-cncr2820760921>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision.

Authors:  Stephanie G Kellermann; Christina A Hamisch; Daniel Rueß; Tobias Blau; Roland Goldbrunner; Harald Treuer; Stefan J Grau; Maximilian I Ruge
Journal:  J Neurooncol       Date:  2017-06-21       Impact factor: 4.130

2.  Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973-1993.

Authors:  Satoshi Kaneko; Kazuhiro Nomura; Takesumi Yoshimura; Naohito Yamaguchi
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

Review 3.  Treating glioblastoma in the elderly.

Authors:  Jaime Gállego Pérez-Larraya; Jean-Yves Delattre
Journal:  CNS Oncol       Date:  2012-11

Review 4.  The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis.

Authors:  Paula de Robles; Kirsten M Fiest; Alexandra D Frolkis; Tamara Pringsheim; Callie Atta; Christine St Germaine-Smith; Lundy Day; Darren Lam; Nathalie Jette
Journal:  Neuro Oncol       Date:  2014-10-13       Impact factor: 12.300

Review 5.  Towards personalized therapy for patients with glioblastoma.

Authors:  Katsuyuki Shirai; Arnab Chakravarti
Journal:  Expert Rev Anticancer Ther       Date:  2011-12       Impact factor: 4.512

6.  Glioblastoma multiforme in the elderly: a therapeutic challenge.

Authors:  A Mangiola; G Maira; P De Bonis; M Porso; B Pettorini; G Sabatino; C Anile
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

7.  TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.

Authors:  Xia Zhou; Yadong Yang; Pengcheng Ma; Na Wang; Dong Yang; Qiu Tu; Bin Sun; Tingxiu Xiang; Xudong Zhao; Zongliu Hou; Xiangdong Fang
Journal:  J Neurooncol       Date:  2019-10-11       Impact factor: 4.130

8.  Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours.

Authors:  Michelangelo Bartolo; Chiara Zucchella; Andrea Pace; Gaetano Lanzetta; Carmine Vecchione; Marcello Bartolo; Giovanni Grillea; Mariano Serrao; Cristina Tassorelli; Giorgio Sandrini; Francesco Pierelli
Journal:  J Neurooncol       Date:  2011-11-29       Impact factor: 4.130

9.  Management of epilepsy in brain tumors.

Authors:  Marta Maschio; Umberto Aguglia; Giuliano Avanzini; Paola Banfi; Carla Buttinelli; Giuseppe Capovilla; Marina Maria Luisa Casazza; Gabriella Colicchio; Antonietta Coppola; Cinzia Costa; Filippo Dainese; Ornella Daniele; Roberto De Simone; Marica Eoli; Sara Gasparini; Anna Teresa Giallonardo; Angela La Neve; Andrea Maialetti; Oriano Mecarelli; Marta Melis; Roberto Michelucci; Francesco Paladin; Giada Pauletto; Marta Piccioli; Stefano Quadri; Federica Ranzato; Rosario Rossi; Andrea Salmaggi; Riccardo Terenzi; Paolo Tisei; Flavio Villani; Paolo Vitali; Lucina Carla Vivalda; Gaetano Zaccara; Alessia Zarabla; Ettore Beghi
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

10.  Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population.

Authors:  Saurabh Ray; Machaon M Bonafede; Nimish A Mohile
Journal:  Am Health Drug Benefits       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.